Aprio Wealth Management LLC Buys 4,316 Shares of Pfizer Inc. $PFE

Aprio Wealth Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 26.4% during the first quarter, Holdings Channel.com reports. The firm owned 20,693 shares of the biopharmaceutical company’s stock after purchasing an additional 4,316 shares during the quarter. Aprio Wealth Management LLC’s holdings in Pfizer were worth $524,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the 4th quarter worth approximately $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the first quarter worth $27,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth $28,000. Finally, North Capital Inc. purchased a new stake in shares of Pfizer during the 1st quarter valued at $28,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PFE shares. HSBC dropped their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Berenberg Bank cut their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.76 on Thursday. The business’s 50 day moving average price is $24.83 and its 200 day moving average price is $24.37. The firm has a market cap of $140.75 billion, a P/E ratio of 13.17, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.